Table 1.
Patient characteristics and comorbidities (n = 136)
| Characteristic | ET (n = 72) | PV (n = 46) | PMF (n = 18) | Total (n = 136) | p value |
|---|---|---|---|---|---|
| Age, yr | 64.5 (18–88) | 58.5 (23–86) | 64 (40–86) | 62 (18–88) | 0.23 |
| Total years in cohort, yr | 304 | 224 | 45 | 573 | |
| Female sex | 32 (44.4) | 12 (26.1) | 6 (33.3) | 50 (36.8) | 0.12 |
| Palpable splenomegaly | 23 (31.9) | 29 (63) | 16 (88.9) | 68 (50) | < 0.01 |
| JAK2 mutation | 38 (52.8) | 38 (82.6) | 16 (88.9) | 92 (67.6) | < 0.01 |
| WBC, 109/L | 12.2 ± 8.3 | 14.2 ± 7.4 | 10.3 ± 6.2 | 12.6 ± 7.8 | 0.17 |
| Hemoglobin, g/dL | 13.3 ± 2.2 | 19.5 ± 1.7 | 10.8 ± 2.8 | 15.1 ± 3.9 | < 0.01 |
| Platelet, 109/L | 904 ± 349 | 392 ± 182 | 381 ± 344 | 661 ± 396 | < 0.01 |
| Neutrophil, 109/L | 8.5 ± 7.6 | 10.8 ± 6.3 | 6.4 ± 3.8 | 9.0 ± 6.9 | 0.05 |
| Monocyte, 109/L | 0.7 ± 0.5 | 0.7 ± 0.5 | 0.6 ± 0.5 | 0.7 ± 0.5 | 0.49 |
| LDH, U/L | 540 ± 200 | 565 ± 199 | 1160 ± 587 | 622 ± 336 | < 0.01 |
| eGFR, mL/min/1.73 m2 | 81.4 (34.6–129.5) | 83.2 (35.3–126.1) | 89.3 (61.7–118.6) | 82.1 (34.6–129.5) | 0.58 |
| Treatment | |||||
| Hydroxyurea | 46 (63.9) | 30 (65.2) | 7 (38.9) | 83 (61) | 0.12 |
| Anagleride | 17 (23.6) | 2 (4.3) | 0 | 19 (14) | < 0.01 |
| Phlebotomy | 0 | 39 (84.8) | 0 | 39 (28.7) | < 0.01 |
| Comorbidities | |||||
| Hypertension | 32 (44.4) | 22 (47.8) | 5 (27.8) | 59 (43.3) | 0.34 |
| Diabetes mellitus | 14 (19.4) | 8 (17.4) | 3 (16.7) | 25 (18.4) | 0.95 |
| Smokers/prior smokers | 16 (22.2) | 28 (60.9) | 3 (16.7) | 47 (34.6) | < 0.01 |
| IHDa | 8 (11.1) | 4 (8.7) | 1 (5.6) | 13 (9.6) | 0.39 |
| Strokeb | 21 (29.2) | 7 (15.2) | 2 (11.1) | 30 (22.1) | 0.08 |
| Other atherosclerotic diseasec | 5 (6.9) | 2 (4.3) | 0 | 7 (5.1) | 0.64 |
| DVT/PTE | 1 (1.4) | 3 (6.5) | 0 | 4 (2.9) | 0.35 |
| Kidney diseased | 4 (5.6) | 8 (17.4) | 0 | 12 (8.8) | 0.04 |
| Cancers before diagnosis of MPN | 4 (5.6) | 3 (6.5) | 2 (11.1) | 9 (6.6) | 0.71 |
| Cancers after diagnosis of MPN | 3 (4.2) | 4 (8.7) | 0 | 7 (5.1) | 0.47 |
| Transformation | < 0.01 | ||||
| Myelofibrosis | 4 (5.6) | 1 (2.2) | 0 | 5 (3.7) | |
| MDS | 0 | 1 (2.2) | 0 | 1 (0.7) | |
| AML | 1 (1.4) | 0 | 4 (22.2) | 5 (3.7) |
Values are presented as median (range), number (%), or mean ± SD.
ET, essential thrombocythemia; PV, polycythemia vera; PMF, primary myelofibrosis; WBC, white blood cell; LDH, lactate dehydrogenase; eGFR, estimated glomerular filtration rate; IHD, ischemic heart disease; DVT, deep-vein thrombosis, PTE, pulmonary thromboembolism; MPN, myeloproliferative neoplasm; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia.
a
Angina pectoris including myocardial infarction.
b
Cerebral hemorrhage and cerebral infarction.
c
Arterial aneurism and thrombosis, intermittent claudication.
d
Proteinuria (> 3 g/day) or glomerulonephritis.